Novel agents and new therapeutic approaches for treatment of multiple myeloma

doi:10.5662/wjm.v4.i2.73

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 2

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7842)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

480

WORD

353

HTML

4183

Figures (1-3)

288

Tables (1-4)

224

Sum=5528

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1053

Download

1261

Sum=2314

Jun 26, 2014 (publication date) through Nov 27, 2024

Times Cited of This Article

Times Cited (27)

Journal Information of This Article

Publication Name

World Journal of Methodology

ISSN

2222-0682

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Methodol. Jun 26, 2014; 4(2): 73-90
Published online Jun 26, 2014. doi: 10.5662/wjm.v4.i2.73

Table 1 Bortezomib-based induction, immunomodulatory-based induction, bortezomib-based and immunomodulatory-based regimens for transplant-elegible patients

Regimen	Drugs	Ref.
Bortezomib-based induction
VD	Bortezomib/dexamethasone	[12,13]
VTD	Bortezomib/thalidomide/dexamethasone	[12,13]
CyBorD or VCD	Bortezomib/cyclophosphamide/dexamethasone	[14-16]
VCRD	Bortezomib/cyclophosphamide/lenalidomide/dexamethasone	[14-16]
VRD	Bortezomib/lenalidomide/dexamethasone	[14-16]
Immunomodulatory-based induction
TD	Thalidomide/dexamethasone	[19,20]
VTD	Bortezomib/thalidomide/dexamethasone	[12,13]
Rd	Lenalidomide/low-dose dexamethasone	[23]
VCRD	Bortezomib/cyclophosphamide/lenalidomide/dexamethasone	[14-16]
VRD	Bortezomib/lenalidomide/dexamethasone	[14-16]
Bortezomib-based
VMP	Bortezomib/melphalan/prednisone	[29-31]
VMPT	Bortezomib/melphalan/prednisone/thalidomide	[30]
Immunomodulatory-based
TD	Thalidomide/dexamethasone	[32]
MPT	Melphalan/prednisone/thalidomide	[40,41]
Rd	Lenalidomide/low-dose dexamethasone	[44]
RD	Lenalidomide/high-dose dexamethasone	[43]
MPR	Melphalan/prednisone/lenalidomide	[45]

Citation: Ria R, Reale A, Vacca A. Novel agents and new therapeutic approaches for treatment of multiple myeloma. World J Methodol 2014; 4(2): 73-90
URL: https://www.wjgnet.com/2222-0682/full/v4/i2/73.htm
DOI: https://dx.doi.org/10.5662/wjm.v4.i2.73